Overview

Evaluation HEC121120 Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study

Status:
Recruiting

Trial end date:
2022-09-15

Target enrollment:

Participant gender:

Summary

The Safety, Tolerability, Pharmacokinetics and antiviral activity Study of Anti hepatitis B virus treatment drug HEC121120 in Healthy subjects and in patients with chronic hepatitis B

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Sunshine Lake Pharma Co., Ltd.

Treatments:

Entecavir